Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang

Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0133

View: 838 Download: 55 Crossref: 1

Original Article

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):382-393. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987

View: 2638 Download: 419 Crossref: 12

Editorial

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):705-708. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

View: 2115 Download: 69 Web of Science: 3 Crossref: 3

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0202

View: 7836 Download: 206 Web of Science: 29 Crossref: 26

Original Article

High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease

Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao

Received September 21, 2024 Accepted January 1, 2025

DOI: https://doi.org/10.3350/cmh.2024.0822 [Accepted]

View: 1161 Download: 119

1 |

Viewed By 8997	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7682	MAFLD: How is it different from NAFLD?
Viewed By 5548	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5155	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4614	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 293	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 204	MAFLD: How is it different from NAFLD?
Cited By 103	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes

Search